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Abstract
Introduction: A better understanding of pediatric antiretroviral therapy (ART) adherence in sub-Saharan Africa is necessary
to develop interventions to sustain high levels of adherence.
Methodology/Principal Findings: Adherence among 96 HIV-infected Zambian children (median age 6, interquartile range
[IQR] 2,9) initiating fixed-dose combination ART was measured prospectively (median 23 months; IQR 20,26) with caregiver
report, clinic and unannounced home-based pill counts, and medication event monitoring systems (MEMS). HIV-1 RNA was
determined at 48 weeks. Child and caregiver characteristics, socio-demographic status, and treatment-related factors were
assessed as predictors of adherence. Median adherence was 97.4% (IQR 96.1,98.4%) by visual analog scale, 94.8% (IQR
86,100%) by caregiver-reported last missed dose, 96.9% (IQR 94.5,98.2%) by clinic pill count, 93.4% (IQR 90.2,96.7%) by
unannounced home-based pill count, and 94.8% (IQR 87.8,97.7%) by MEMS. At 48 weeks, 72.6% of children had HIV-1 RNA
,50 copies/ml. Agreement among adherence measures was poor; only MEMS was significantly associated with viral
suppression (p=0.013). Predictors of poor adherence included changing residence, school attendance, lack of HIV
disclosure to children aged nine to 15 years, and increasing household income.
Conclusions/Significance: Adherence among children taking fixed-dose combination ART in sub-Saharan Africa is high and
sustained over two years. However, certain groups are at risk for treatment failure, including children with disrupted
routines, no knowledge of their HIV diagnosis among older children, and relatively high household income, possibly
reflecting greater social support in the setting of greater poverty.
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Introduction
Over two million children under 15 years of age live with HIV/
AIDS, 90% of whom reside in sub-Saharan Africa.[1] Efforts to
provide children with antiretroviral therapy (ART) are increasing.
By the end of 2008, 275,000 children had received ART,
representing 38% of children estimated to need it.[2]
ART use in HIV-infected children leads to reduced plasma HIV
RNA levels, increased CD4 cell counts, decreased incidence of
opportunistic infections, improved growth and development, and
decreased morbidity and mortality.[3,4] High levels of sustained
adherence, however, are needed to achieve these benefits.[5,6]
A review of ART adherence in low and middle-income countries
found a range in adherence level estimates from 49% to 100% with
76% of articles reporting .75% adherence.[7] The factors
associated with adherence behavior among children are poorly
understood and likely different from adults. A better understanding
of the determinants of adherence is necessary to improve adherence
and treatment outcomes. This need is particularly important in
resource-constrained settings with limited treatment options.
This study presents adherence data from 96 Zambian children
who were followed prospectively for up to two years. The two
goals of the study were to 1) conduct a comparative evaluation of
several widely used adherence measures; and 2) identify factors
associated with adherence to fixed-dose combination (FDC) tablets
in a resource-limited setting.
Methods
Ethical statement
Ethical approval for the parent trial CHAPAS-1 (Children with
HIV in Africa – Pharmacokinetics and Adherence of Simple
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18505antiretroviral regimens, ISRCTN 31084535) and the adherence
study was given by the University of Zambia and the University
College, London. Informed, written consent was obtained from
the parent or guardian of all participants. If he or she could not
write, a witnessed thumbprint was accepted.
Study population–The parent trial CHAPAS-1
The study population was drawn from the CHAPAS-1 trial,
which was a randomized study of nevirapine (NVP) dose
escalation among HIV-infected children initiating ART.[8] All
children were treated at the University Teaching Hospital in
Lusaka, Zambia. Children randomized to initiate NVP at full dose
used FDC tablets of stavudine (d4T), lamivudine (3TC), and NVP
(Triomune Baby/Junior) twice daily. Children randomized to
escalate their dose of NVP used Triomune Baby/Junior once daily
for 14 days, together with an FDC of d4T and 3TC (Lamivir-S)
once daily. After 14 days Lamivir-S was stopped and children
continued on twice daily Triomune Baby/Junior. FDCs were
dissolvable, scored mini-tablets administered according to World
Health Organization weight bands.[9] The CHAPAS-1 trial ran
from February 2006 to December 2008, enrolling 211 children.
Adherence measures in the parent trial
Adherence was measured at four-weekly clinic visits with pill
counts, caregiver report of the last missed dose of ART (i.e.
caregivers were asked ‘‘When did your child last miss any ART:
within the last week, 1–2 weeks, 2–4 weeks, 1–3 months, nothing
in 3 months?’’), and a visual analog scale (VAS), where caregivers
indicated the child’s adherence on a line marked with ‘‘none
given’’ and ‘‘all given’’ at the ends and ‘‘half given’’ at the mid-
point. Socio-economic data was collected at baseline and after six
months, one year, and two years. Viral load was determined at 48-
weeks from samples separated and frozen on site and processed at
the Joint Clinical Research Centre Laboratory in Kampala,
Uganda (Roche Amplicor Monitor version1.5 ultrasensitive assay).
Adherence measures in the sub-study
The adherence sub-study ran from May 2006 until December
2008. It included two additional measures: 1) electronic monitor-
ing with MEMS (Medication Event Monitoring System, Aardex,
Switzerland) caps; and 2) unannounced monthly home visits for
further pill counts. MEMS data was downloaded at each four-
weekly clinic visit. Children stopped using MEMS caps when
tuberculosis treatment required substitution of efavirenz for
nevirapine and hence separate drugs rather than the FDC tablets.
Drugs were dispensed four-weekly, and no pharmacy stock outs
occurred during the trial.
Analysis methods
To analyze agreement among methods, the four-weekly
measurements of each child were averaged over the total follow-
up to produce a summary adherence measure. For analysis of
factors associated with MEMS adherence, data was aggregated
into 12-week periods for each child, reducing random fluctuation
and allowing a more prolonged effect of cofactors. The last MEMS
period for most children covered ,12 weeks.
Clinic pill counts were adjusted for children returning off-
schedule. For each four-week period, MEMS data was used to
calculate ‘taking adherence’; two or more bottle openings
represented an adherent day, and days with a single opening
counted as half-adherent. Adherence data from the first four weeks
of treatment was not analyzed since dose escalation used two
different tablets. For each MEMS cap, the last four-week time
period was excluded if data were missing at the end of the period,
because this finding commonly signalled cap failure or device non-
use. For the last reported missed dose, each four-week period was
classified as adherent or non-adherent, with an adherent period
defined as no missed dose reported. Each child’s summary
adherence measure was the percentage of adherent periods (e.g.
no missed doses reported at nine of ten follow-up visits equals 90%
adherence).
Agreement between adherence methods was assessed by Kappa
statistics and Bland/Altman plots.[10] To calculate Kappa
statistics, children were categorized as having adherence ,80%
versus $80% and ,95% versus $95% for each adherence
method. Bland/Altman plots illustrate agreement between two
methods by plotting the difference between each pair of
measurements against their mean.
Associations were investigated between viral load and average
adherence at 48 weeks for each measure. Undetectable viral load
was defined as ,50 copies/ml, as adherence over the preceding 48
weeks was categorized as ,80% versus $80% and ,95% versus
$95%. Where Fisher’s exact tests found significant associations,
evidence for non-linearity in the relationship between viral load
failure and adherence was explored via logistic regression using
cubic splines for adherence.[11]
To identify predictors of adherence, random-effects regressions
were used to model repeated measures from each child with time-
updated factors. Poisson regressions were used to model the
number of non-adherent days in each 12-week period with
normally distributed between-subject error on the log-linear scale.
Factors investigated included child and caregiver characteristics,
socio-demographic status, and treatment-related factors. Univar-
iate models were fitted separately to each factor, and those with
significant univariate associations (p#0.10) were used in a
backward elimination (exit p.0.05) to create a multivariate
model. Evidence of non-linear associations was investigated using
cubic splines, with non-linearity represented by piece wise linear
factors in final models.[11]
All analyses were performed using Stata statistical software
(release 11, StataCorp, USA).
Results
The first 107 consenting children were enrolled into the
adherence sub-study. These children were statistically similar to
other children in the parent study in age, sex, and disease stage
(p.0.05). Nine children in the adherence sub-study died or were
lost to follow-up shortly after randomisation, and two others had
no MEMS data (one switched early to efavirenz, one stopped using
MEMS for unknown reasons), leaving 96 participants for analysis.
The median age at ART initiation was 6 (IQR 2,9) years, and 53
(55%) participants were male (Table 1). Many participants had
advanced HIV disease at enrolment and were severely wasted and
stunted. The primary caregiver was the mother for 68% of
children. Sixty-six percent of children had more than one
caregiver, with caregiver defined as someone who gives the child
medication. In this primarily urban population, family size and
dwellings were generally small, but 65% had electricity. Levels of
poverty were high; median monthly household income was
398,000 Kwacha (US$79) and half of households spent $25%
of income on food.
Total follow-up was 164.4 person years (pyrs) from 2134 clinic
visits, with a median of 23 follow-up visits per child (IQR 20,26:
range 1,31). Follow-up was shorter for MEMS caps (113.5 pyrs), as
23 children had caps replaced during the study because of loss or
failure. Additionally, MEMS follow-up ended for 30 children in
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MEMS caps. Follow-up from home visits was also shorter because
they were often prevented by transport problems and the visit
occurred approximately three weeks into each month; 1275 total
visits took place covering 71.7 pyrs. Three children included in the
analysis died and five others were lost to follow-up. The median
follow-up among these eight children was 14 weeks (IQR 8,36).
Overall adherence to twice daily FDC was high (Table 2). VAS
and clinic pill counts indicated median adherence of 97.4% (IQR
96.1,98.4%) and 96.9% (IQR 94.5,98.2%), respectively. These
clinic-based measures also indicated relatively few children with
low adherence. Sixteen percent had adherence ,95% by VAS,
and 31% had adherence ,95% by clinic-based pill count. No
children had adherence ,80% by either method. Caregivers were
asked the last missed dose question a median of 23 times (IQR
20,26), and the median number of times missed doses were
reported was 1 (IQR 0,3), giving a median adherence of 94.8%
(IQR 86,100%). Over 25% of caregivers reported no missed doses
ever. Median adherence from unannounced home-visit pill counts
and MEMS data was also high at 93.4% (IQR 90.2,96.7%) and
94.8% (IQR 87.8,97.7%), respectively. These methods, however,
also indicated higher levels of incomplete adherence compared to
clinic-based measures. Unannounced home-visit pill counts
indicated adherence ,95% and ,80% in 62% and 10% of
children, while MEMS data indicated adherence ,95% and
,80% in 51% and 13% of children, respectively. The timing of
MEMS events was well distributed in that two openings were at
least eight hours apart for 96% of adherent days.
Agreement between methods was poor with low Kappa statistic
values (Table 2). Unannounced home-based pill counts had higher
agreement with MEMS data (Kappa=0.42; 95%CI 0.26,0.58)
than either clinic-based measure. The relatively good agreement
between VAS and clinic pill counts (Kappa=0.52; 95%CI
0.34,0.70) resulted from 70% of children having adherence
.95% with both methods. The highest agreement with the last
missed dose question was observed with MEMS data (Kappa=
0.31; 95%CI 0.16,0.46), while the lowest agreement was with the
VAS (Kappa=0.11; 95%CI 0.0,0.23). The last missed dose
question does not measure how much ART was missed; rather, it
indicates that not all doses were taken and should be interpreted
separately. Disagreement between methods appeared to be greater
in some children compared to others. Eight children accounted for
over half of the 107 clinic visits in which MEMS data indicated
adherence ,80% and clinic pill counts simultaneously indicated
adherence .95%.
Agreement between methods is further illustrated by Bland/
Altman plots (Figure 1), which show that, when compared to
MEMS data or home-based pill counts, clinic pill counts and VAS
consistently estimated higher adherence with almost no data above
the zero line. Better agreement was shown between MEMS and
home-based pill counts, but again a tendency for pill counts to give
higher estimates was observed. The plot of clinic pill counts against
VAS shows the very limited data range. For the last missed dose
question, the highest agreement was seen with MEMS data, while
other clinic-based measures consistently gave higher estimates of
adherence.
Viral load was measured at 48 weeks in 73 of 96 children (76%)
and was ,50 copies/ml in 53 of 73 (73%). Data for 23 children
were unavailable because of death (N=2), loss to follow-up
(N=4), or inadequate samples (N=17). Viral load was signifi-
cantly associated with poor MEMS adherence (p=0.013); five of
seven children (71%) with adherence ,80% had detectable viral
load (Table 3). No other adherence measure had a significant
association with viral load. Odds of suppression increased linearly
Table 1. Characteristics at ART initiation.
N
a (%)
a
Characteristic 96 (100)
Child
Sex Male 53 (55)
Age, years Median (IQR) 6 (2,9)
WHO stage 3 60 (63)
43 6 ( 3 7 )
CD4% $15% 34 (35)
,15%, $5% 53 (55)
,5% 9 (9)
CD4 in children .5 years Median (IQR) 379 (267,692)
Weight-for-age
b Median (IQR) -3.2 (-4.2, -2.1)
Z #-2SD 73 (76)
Height-for-age
b Median (IQR) -3.1 (-4.1, -2.2)
Z #-2SD 74 (77)
Attending school
c Yes 44 (46)
Knows their HIV status (9–15 years)
c Yes 2 (2)
Caregiver
Primary caregiver Mother 65 (68)
Aunt 13 (14)
Grandmother 10 (10)
Father 4 (4)
Other 4 (4)
No. of caregivers 1 32 (33)
25 6 ( 5 8 )
3 8 (8)
Household
c
No. of other children 0 17 (18)
12 0 ( 2 1 )
22 9 ( 3 1 )
$32 9 ( 3 1 )
Other household member on ART Yes 18 (19)
No. of rooms 1–2 46 (48)
.34 9 ( 5 2 )
Electricity Yes 61 (64)
Domestic tap Yes 41 (43)
Monthly income (in 1000 Kwacha) Median (IQR) 398 (250,700)
Main income source Market worker 49 (52)
Driver 5 (5)
Public servant 13 (14)
Farmer 6 (6)
Security/police 4 (4)
Other 18 (19)
Food as percent expenditure Median (IQR) 27 (20,47)
a. Other statistics are indicated in the second column.
b. UK 1990 growth reference; WHO 2007 reference only available to 10 years. For
children to age 10, the average UK weight Z-score was 0.5 lower than the
WHO reference and the average UK height Z-score was 0.1 higher than WHO
reference.
c. Missing data for one child.
doi:10.1371/journal.pone.0018505.t001
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a specific threshold (non-linearity p=0.47).
MEMS follow-up ranged between one and ten 12-week periods
per child (median=5; IQR 4,7). The outcome for each time
period was the number of days of missed ART. Socio-economic
data was not available for ten children until the six-month time
period. A total of 509 time periods were analyzed from 95
children. The median number of missed ART days in the 12-week
periods was 4 (IQR 1,10).
Factors that were not significant in univariate analyses were
early or late entry into the trial, change of primary caregiver, total
number of changes in caregiver, child gives himself or herself
ART, socioeconomic index (a first principal component based on
household possessions), and change of dose. Factors significant in
univariate analyses but not selected in the final multivariate model
were the number of tablets daily, differing morning and evening
ART doses, other household member on ART, main occupational
source of household income, and percentage of household income
spent on food.
The factors included in the multivariate model are shown in
Table 4. Several child characteristics were found to significantly
affect MEMS adherence. A complex relationship was observed
between age and sex. Missed ART days among boys decreased by
44% annually up to five years, increased by 56% between five and
ten years, and decreased by 25% above ten years. Missed ART
days among girls decreased by 27% annually up to five years,
continued to decrease by 10% between five and ten years, and
increased by 31% above ten years. Across the age range, missed
ART days were not consistently higher in boys or girls, but were
significantly higher in girls at age five (IRR 3.50; 95%CI
1.20,10.21) and significantly lower in girls at age ten (IRR 0.23;
95%CI 0.08,0.65).
The number of missed ART days increased by an average of
34% with a unit increase in weight-for-age Z-score (p,0.001) and
by 5% for each increase in CD4% of 5% (p=0.016). A child’s
knowledge of his/her HIV status and attendance at school were
strongly associated with age, but remained independent predictors
with adjustment for age. Two children knew their HIV status at
baseline, and 24 others aged nine to 15 years learned it during the
trial. The average number of missed ART days was 46% higher
among those attending school (p=0.003), but 38% lower among
children knowing their status compared to children who did not
know (p=0.001).
A significant improvement in adherence was also observed after
six months (p,0.001), which remained when analysis was
restricted to children with $18 months follow-up.
Caregiver and household characteristics were also significant
covariates. The highest adherence was observed where the child’s
mother was the primary caregiver (p,0.001), and improved by
23% if the child had multiple caregivers, but the effect of two
caregivers was similar to three or more (p,0.001). Adherence was
25% worse among children whose caregivers reported giving ART
because they knew why their child needed it versus caregivers who
did not know why (p,0.001). Missed ART days increased by 57%
after changing address (p,0.001), and by 26% for each other child
in the household (p,0.001). Missed ART days increased by 8%
per 100,000 Kwacha (US$20) income up to 800,000 Kwacha
(US$160) per month, and did not increase further at higher
incomes (p=0.001). Total household income was not directly
adjusted for household size, although the number of caregivers
and other children was included in the model.
Discussion
This study is the first in-depth analysis of ART adherence
among HIV-infected children with nearly two years of follow-up in
sub-Saharan Africa. The high levels of overall adherence are
encouraging, as they are likely adequate for viral suppression with
Table 2. Follow-up, summary of adherence measures and agreement between methods.
Visual Analogue Last missed dose
Pill count
MEMS Home visit Clinic visit Scale (VAS) question
Follow-up, by method
Total follow-up (pyrs) 113.5 71.7 163.2 163.3 163.3
Number of children 96 96 96 96 96
Median (IQR) visits/child 15 (10,20) 15 (10,18) 23 (20,26) 23 (20,26) 23 (20,26)
Summary of adherence, by method
Adherence (median) 94.8% 93.4% 96.9% 97.4% 94.8%
a
IQR 87.8,97.7 90.2,96.7 94.5,98.2 96.1,98.4 86,0,100
Range 31.3,100 67.5,100 83.4,100 87.5,100 64.3,100
Adherence ,95%, n (%) 49 (51.0) 59 (61.5) 30 (31.2) 15 (15.6) 48 (50.0)
Adherence ,80%, n (%) 12 (12.5) 10 (10.4) 0 0 15 (15.6)
Agreement between methods, Kappa statistic (95% CI)
MEMS 0.42 (0.26,0.58) 0.19 (0.04,0.35) 0.05 (0.0,0.18) 0.31
b (0.16,0.46)
Home visit 0.36 (0.20,0.53) 0.18 (0.05,0.30) 0.24 (0.08,0.39)
Clinic visit 0.52 (0.34,0.70) 0.15 (0.0,0.30)
VAS 0.11 (0.0,0.23)
a. Percentage of follow-up visits with no missed dose reported during previous month.
b. Agreement between the last missed dose question and other methods should be interpreted separately (e.g. 90% adherent for the last missed dose means that no
treatment was missed in nine periods out of ten, but does not indicate the level of non-adherence in those periods).
doi:10.1371/journal.pone.0018505.t002
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available for children in developing settings.[9,12] Some of the
high adherence may have been facilitated by the convenience of
taking FDC tablets.[13] In the absence of FDC, pediatric regimens
are commonly complex, involving multiple medications and
syrups that change frequently according to child development
and drug availability.[14] The lack of a comparison group,
however, limits this conclusion. The longitudinal improvement in
adherence is also very positive and contrasts with a recent study of
mother-child dyads in Kampala showing decreasing trends in
adherence.[15] The findings that 27% of children had detectable
viral load at 48 weeks and 18% of children had ,80% adherence
by MEMS, however, indicate that subpopulations are at risk for
treatment failure.
The negative effect of change in residence suggests the child’s
adherence may reflect household instability and some aspects of
routine may be important, although no independent effect was
seen for change of caregiver or change of dose. The negative
impact of school attendance may also reflect disruption of routine,
as children may board at the school, take breaks between
semesters, and may have difficulty taking their medicine
confidentially.
Effects of HIV disclosure to children on adherence are
complex,[16] and little is known in sub-Saharan Africa. Two
qualitative studies identified limited communication between
caregivers and children, as well as the need for better support
throughout the disclosure process.[17,18] The improved adher-
ence with HIV disclosure to the child suggests that full
understanding of HIV medications is important in these children.
Paradoxically, adherence was worse when caregivers had good
knowledge of why their child needed ART. This association may
be explained by the finding that improved caregiver knowledge
was significantly associated with another household member being
on ART (OR=1.64, p=0.021), reflecting households with greater
HIV burden. Further exploration of this important issue is needed.
The adherence pattern seen with household incomes suggests
that families with fewer financial resources have better adherence
than those with higher incomes. Better adherence in the setting of
low resources may be explained by enhanced social support
among people living in extreme poverty, which has been proposed
as an explanation for good adherence among adults in sub-
Saharan Africa.[19] According to this theory, individuals taking
ART overcome economic obstacles to adherence through the
assistance of family and other supporters (e.g. borrowing transport
Figure 1. Agreement between measures (as shown by the difference between methods versus mean adherence value for each
child). The Bland-Altman plots in this figure show pair wise agreement between adherence methods. Each plot indicates the difference between two
methods on the vertical axis against the mean of the same methods on the horizontal axis. Data points above the zero line occur when the first
method shows higher adherence than the second. On the horizontal axis, data points to the right indicate high adherence from both methods, in
which case the maximum possible difference between them is shown by the angled lines.
doi:10.1371/journal.pone.0018505.g001
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In exchange, these supporters expect adherence, creating a
responsibility for patients to adhere. Indeed, the worsened
adherence seen with increased numbers of children in the
household may reflect economic and logistical challenges to
sustained HIV care. This finding should not be misinterpreted to
suggest that poverty is a means to improve adherence. Rather,
social support differs by socio-economic level, and greater reliance
on close social networks among people living in poverty may
enhance adherence. The worsened adherence with increased
weight-for-age Z-score and CD4% may reflect decreased motiva-
tion to adhere as children regain health and have fewer HIV-
related symptoms.[20]
The influence of age and sex on adherence was notable. Older
children are often reported to have lower adherence than both
younger children and adults.[14] Relatively few studies on this topic
have been published from sub-Saharan Africa; however, one from
South Africa found lower adherence in adolescents compared to
adults,[21] while another in Uganda found no difference in
adherence by age or sex.[22] The authors are unaware of any
studies examining the interaction of age and sex on adherence. The
finding of worsening adherence for girls and improving adherence
for boys over ten years could suggest a cultural bias toward
supporting males. Alternatively, thenumberof children at this ageis
relatively small and this finding could be due to chance.
Although this study did not assess interventions to improve
adherence, the findings suggest several potentially modifiable
factors, including leveraging social support to overcome economic
barriers to care, stabilizing routine possibly through additional
caregiver support, and/or disclosing HIV to older children.
Additionally, unexplained between-child variation remained in the
final regression model, suggesting the presence of other unknown
reasons why some children have consistently better adherence
than others.
This study used multiple adherence measures, as no gold
standard exists and each method has advantages and
disadvantages. Subjectively reported adherence is easy to
collect, but often felt to overestimate adherence.[23] Clinic pill
counts are also relatively easy to perform and objective;
however, participants may manipulate pills to appear more
adherent,[24] which may explain the clustering of discordant
MEMS and clinic pill count data within certain children.
Home-based pill counts are performed unannounced, such that
participants have little opportunity for pill manipulation, but
they are resource-intensive.[25] MEMS is generally accepted as
the industry standard for adherence measurement,[26] although
they are expensive and preclude the use of pill box
organizers.[27] Moreover, participants may open the cap
without removing pills, remove multiple pills at a time, or
simply not use it.[28]
As expected, median adherence in this study was higher for
self-reported adherence and clinic pill counts compared to
unannounced home-based pill counts and MEMS. MEMS was
selected as the best measure in this study population because it
had the least evidence of higher estimates compared to other
measures and had the only significant association with viral load.
Moreover, more precise measures by definition have greater
ability to distinguish among different levels of adherence
compared to less precise measures. MEMS gave the widest
distribution of adherence, suggesting it was more precise than
the other measures. The MEMS data also showed distinct
morning and evening peaks, which may reflect true pill taking
behavior.
Caregiver-report of last missed ART dose had a relatively
high agreement with MEMS. These findings suggest that certain
self-report questions may perform better than others. Indeed,
various recall periods and question formats have been shown to
correlate differently with MEMS.[29] Given the overall high
adherence in this study, a missed dose may have been fairly
easy to recall and more sensitive in detecting incomplete
adherence than recalling the number or percentage of doses
missed.[30]
This study had several limitations. First, only MEMS data was
used to assess for predictors of adherence. Second, the study
population was drawn from a clinical trial and the children may
have been more motivated to adhere than children outside the
research setting. Additionally, approximately 10% of participants
did not complete the study, and their adherence behavior may
have differed from children remaining in the study. Finally, the
process of measuring adherence can improve adherence,[31] but
the effect is usually temporary and affects a minority of
individuals.[32]
In conclusion, this study provides encouraging data about high,
sustained long-term adherence among children taking fixed-dose
combination ART in sub-Saharan Africa. Multiple measures of
adherence were used to estimate adherence behavior, and all
suggest adherence is in the range needed for treatment success.
That said, subgroups at risk were identified, including children
with disrupted routine, no knowledge of their HIV infection, and
relatively high incomes. Future research should focus on
developing interventions to support such children.
Table 3. Association between adherence measures and viral
load.
Viral load
,50 copies/
ml
$50 copies/
ml
N( % ) N( % )
53 (73%) 20 (27%) N P
MEMS adherence
$95% 35 (81%) 8 (19%) 43 0.013
$80%,,95% 15 (68%) 7 (32%) 22
,80% 2 (29%) 5 (71%) 7
Home visit pill count
$95% 21 (70%) 9 (30%) 30 0.91
$80%,,95% 29 (74%) 10 (26%) 39
,80% 3 (75%) 1 (25%) 4
Clinic based pill count
$95% 27 (67%) 13 (33%) 40 0.31
$80%,,95% 26 (79%) 7 (21%) 33
,80% 0 0 0
Visual analogue scale
$95% 32 (70%) 14 (30%) 46 0.59
$80%,,95% 21 (78%) 6 (22%) 27
,80% 0 0 0
Last missed dose
$95% 24 (77%) 7 (23%) 31 0.70
$80%,,95% 19 (68%) 9 (32%) 28
,80% 10 (71%) 4 (29%) 14
doi:10.1371/journal.pone.0018505.t003
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Univariate model Multivariate model
Variable IRR 95%CI P IRR 95%CI P
Child related
Sex
Female 1.35 0.74,2.47 0.323
Age
,5yrs (per year) 1.10 0.96,1.26 ,0.001
5-,10yrs 1.47 1.28,1.69
$10yrs 1.15 0.99,1.34
Age and sex ,0.001
a
boy ,5yrs (per year older) 0.56 0.44,0.72
boy 5-,10yrs 1.56 1.29,1.89
boy $10yrs 0.75 0.60,0.94
girl ,5yrs 0.73 0.56,0.94
girl 5-,10yrs 0.90 0.73,1.11
girl $10yrs 1.31 1.00,1.72
girl : boy at age 5 3.50 1.20,10.21 ,0.001
b
girl : boy at age 10 0.23 0.08,0.65
CD4% (5% higher) 1.10 1.07,1.14 ,0.001 1.05 1.01,1.09 0.016
Weight-for-age Z (unit higher) 1.46 1.34,1.58 ,0.001 1.34 1.20,1.50 ,0.001
Attends school 2.94 2.40,3.61 ,0.001 1.46 1.14,1.88 0.003
Knows their HIV status 0.65 0.50,0.83 0.001 0.62 0.47,0.81 0.001
Caregiver related
Primary caregiver Mother 1.00 ,0.001 1.00 ,0.001
Aunt 2.19 1.61,2.96 2.57 1.84,3.58
Grandparent 1.29 0.91,1.83 1.34 0.91,1.97
Other 1.41 1.09,1.82 1.35 1.01,1.79
No. of caregivers 1 1.00 0.002 1.00 ,0.001
2 0.79 0.70,0.89 0.77 0.68,0.88
$3 0.90 0.74,1.10 0.82 0.66,1.03
Caregiver knowledge of ART 1.37 1.26,1.49 ,0.001 1.25 1.13,1.38 ,0.001
Household related
Change of address 1.33 1.08,1.65 0.008 1.57 1.25,1.97 ,0.001
No. of other children (per child) 1.42 1.31,1.53 ,0.001 1.26 1.15,1.39 ,0.001
Income (per 100,000 Kwacha)
up to 800,000 per month 1.12 1.07,1.17 ,0.001 1.08 1.03,1.14 0.003
above 800,000 per month 1.01 0.99,1.03 0.99 0.96,1.01
Other
Months in study 0–3 1.00 ,0.001 1.00 ,0.001
4–6 1.08 0.95,1.23 0.94 0.82,1.08
7–9 0.93 0.81,1.06 0.77 0.66,0.91
10–12 1.12 0.97,1.28 0.74 0.62,0.88
13–15 1.35 1.17,1.57 0.82 0.66,1.01
16–18 1.43 1.22,1.67 0.90 0.71,1.14
$19 1.90 1.63,2.22 1.18 0.91,1.52
IRR – Incidence rate ratio, all factors time updated except for sex.
a. Overall p-value for age and sex.
b. P-value for interaction between age and sex.
doi:10.1371/journal.pone.0018505.t004
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